The Evolving Arena of Ovarian Cancer Maintenance Therapy.

The Evolving Arena of Ovarian Cancer Maintenance Therapy.
Oncology. 2019 Jul 09;:1-4
Authors: Markman M
Abstract
Based on the results of several phase 3 randomized trials, "maintenance therapy" (prolonged treatment after an initial response to cytotoxic chemotherapy) has assumed a critical role in the routine care of advanced epithelial ovarian cancer. While earlier data had provided support for this therapeutic concept in disease management (e.g., multiple cycles of single-agent paclitaxel following a clinical complete response to a platinum/paclitaxel regimen), more recent data has revealed both the efficacy and safety of the anti-angiogenesis agent, bevacizumab, and several PARP inhibitors when employed in this clinical setting.
PMID: 31288226 [PubMed - as supplied by publisher]

Source: Oncology - July 8, 2019 Category: Cancer & Oncology Authors: Markman M Tags: Oncology Source Type: research